Medical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the appointment of Mr Vince Ippolito as its president.
According to founder and executive director, Matt Callahan, “On behalf of the Board I would like to welcome Vince to Botanix. Vince has an enviable track record of developing and launching more than 20 dermatology products in the US and brings a wealth of knowledge and industry expertise to the Company.
“As Executive Vice President and Chief Commercial Officer, Vince has played a leading role in two large dermatology transactions with a combined valuation of US$7.8bn, including the recent sale of dermatology Anacor to Pfizer for US$5.2bn.”
Mr Ippolito has more than three decades experience in the pharmaceutical industry, including more than 20 years in dermatology.
He most recently served as president and chief operating officer of Dermavant Sciences, a specialty biopharmaceutical company that commercialises products that treat inflammatory skin diseases and medical dermatologic conditions.
Mr Ippolito also sits on the board of Suneva Medical, a privately held regenerative aesthetics company. Prior to his role at Dermavant Sciences, Mr Ippolito served as the chief commercial officer and executive vice president of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company.
During his time at Anacor he was responsible for building the marketing and sales functions and developing the company’s product portfolio, as well as playing a key role in the US$5.2 billion sale to Pfizer.
“I am very excited to be joining the Botanix team and I have been keenly following the Company’s growth for many years," said Mr Ippolito.
"Botanix is uniquely positioned and poised for success with its pipeline of novel therapies that have the potential to meet many unmet patient needs. The Company is also way ahead of the curve with its delivery technology, PermetrexTM, a highly elegant formulation with considerable potential across the broader dermatology space.”
Mr Ippolito will assume responsibility for all of the company’s commercial operations worldwide.